Apixaban understudy for VTE Treatment and Thromboprophylaxis

VTE Treatment (DVT/PE)

• The American College of Chest Physicians recommends apixaban over enoxaparin for acute DVT treatment in non-cancer patients due to comparable efficacy and significantly lower bleeding risk 1
• Apixaban is non-inferior to enoxaparin/warfarin combination therapy for preventing recurrent VTE or VTE-related death, with a relative risk of 0.84 and 95% CI 0.60-1.18 2
• Apixaban demonstrates significantly superior bleeding outcomes with major bleeding at 0.6% versus 1.8% for enoxaparin/warfarin, with a relative risk of 0.31 and 95% CI 0.17-0.55; P<0.001 2

Post-Surgical Thromboprophylaxis

• Apixaban is superior to enoxaparin for VTE prophylaxis after total knee replacement, with a relative risk of 0.62 and 95% CI 0.51-0.74; P<0.0001 3
• Apixaban is superior to enoxaparin 40 mg once daily for hip replacement, with a relative risk of 0.36 and 95% CI 0.22-0.54; P<0.001 3

Medical Thromboprophylaxis

• Apixaban is not superior to enoxaparin for thromboprophylaxis in acutely ill medical patients and carries increased bleeding risk, with a relative risk of 0.87 and 95% CI 0.62-1.23 2
• Major bleeding was significantly higher with apixaban, with a relative risk of 2.58 and 95% CI 1.02-7.24; P<0.04 2

Renal Impairment Considerations

• Apixaban has advantages over enoxaparin in moderate renal impairment, but should be avoided in severe renal dysfunction, with only 27% renal elimination compared to enoxaparin's predominantly renal clearance 2
• Avoid apixaban when CrCl <15 mL/min, as patients with CrCl <25 mL/min were excluded from clinical trials 2
• Enoxaparin requires dose adjustment when CrCl <30 mL/min, making apixaban potentially preferable in moderate renal impairment (CrCl 25-50 mL/min) 4

Apixaban for Patients with End-Stage Renal Disease

Introduction to Apixaban Use

• The American College of Cardiology recommends a dose of 5 mg twice daily for patients with end-stage renal disease (ESRD) under stable hemodialysis, with a reduction to 2.5 mg twice daily for patients aged 80 years or older or weighing 60 kg or less 5

Guidance on Direct Oral Anticoagulants

• The European Society of Cardiology guidelines explicitly recommend not using direct oral anticoagulants (DOAKs) in patients with severe renal impairment, with the exception of Apixaban 6
• The National Comprehensive Cancer Network notes that Edoxaban has insufficient data for safe dosing in patients undergoing hemodialysis 7

Considerations for Apixaban Administration

• The recommended dose for ESRD patients under stable hemodialysis is 5 mg twice daily, with reduction to 2.5 mg twice daily for patients meeting certain criteria, such as age 80 years or older or weight 60 kg or less, as supported by the Journal of the American College of Cardiology 5

Management of Apixaban in Acute Kidney Injury

Introduction to Apixaban Management

• The European Society of Cardiology recommends that apixaban can be continued in stable acute kidney injury (AKI) with a creatinine clearance (CrCl) ≥15 mL/min, but with a dose reduction to 2.5 mg twice daily (BID) and close monitoring 8
• In severe or unstable AKI, the European Heart Journal suggests temporary discontinuation of apixaban and transition to unfractionated heparin (UFH) is safer 8

Apixaban Dosing in Renal Impairment

• The American College of Cardiology recommends apixaban 2.5 mg BID for patients with CrCl 15-29 mL/min, representing a 50% dose reduction from the standard 5 mg BID 9, 8
• The European Society of Cardiology guidelines do not recommend apixaban use in patients with CrCl <15 mL/min or those on dialysis 9

Monitoring and Transition Strategy

• The European Heart Journal suggests monitoring renal function daily until stable in patients with AKI, and assessing for bleeding risk factors using the HAS-BLED score 8
• When transitioning from apixaban to UFH in AKI, it is recommended to discontinue apixaban and wait for apixaban clearance before initiating UFH, with monitoring of heparin anti-Xa levels to avoid supratherapeutic anticoagulation 8

Bleeding Risk and Anticoagulant-Related Nephropathy

• The Stroke journal reports that major bleeding rates with apixaban in AKI are higher than typically reported, with a rate of 7.8% in one study 10, 11
• The Journal of the American College of Cardiology notes that apixaban can cause or worsen AKI through anticoagulant-related nephropathy (ARN), manifesting as acute tubular necrosis with occlusive red blood cell casts from glomerular hemorrhage 9